[CAR T-cell therapy and bispecific antibodies for relapsed/refractory follicular lymphoma].

Shinichi Makita
{"title":"[CAR T-cell therapy and bispecific antibodies for relapsed/refractory follicular lymphoma].","authors":"Shinichi Makita","doi":"10.11406/rinketsu.66.424","DOIUrl":null,"url":null,"abstract":"<p><p>Follicular lymphoma (FL) is the second most common lymphoma subtype diagnosed in Japan. Although FL is not curable, it generally has an indolent clinical course in the absence of histologic transformation to aggressive B-cell lymphoma. However, subsets of patients, including those with progression of disease within 24 months (POD24) and those refractory to rituximab and/or alkylators, have a worse prognosis when treated with conventional cytotoxic chemotherapies. Currently, several novel immunotherapies including chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody (BsAb) therapy are under development for the treatment of B-cell non-Hodgkin lymphomas. Several randomized studies in relapsed/refractory diffuse large B-cell lymphoma have already demonstrated the superiority of novel immunotherapies over cytotoxic chemotherapy. Several single-arm pivotal studies of CAR T-cell therapies and BsAb therapies for relapsed/refractory FL have been conducted recently. Some of these agents have already been approved for the treatment of relapsed/refractory FL and are changing clinical practice dramatically. This manuscript summarizes available clinical data on CAR T-cell therapy and BsAb therapy for FL and briefly discusses future prospects.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 6","pages":"424-431"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"[Rinsho ketsueki] The Japanese journal of clinical hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11406/rinketsu.66.424","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Follicular lymphoma (FL) is the second most common lymphoma subtype diagnosed in Japan. Although FL is not curable, it generally has an indolent clinical course in the absence of histologic transformation to aggressive B-cell lymphoma. However, subsets of patients, including those with progression of disease within 24 months (POD24) and those refractory to rituximab and/or alkylators, have a worse prognosis when treated with conventional cytotoxic chemotherapies. Currently, several novel immunotherapies including chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody (BsAb) therapy are under development for the treatment of B-cell non-Hodgkin lymphomas. Several randomized studies in relapsed/refractory diffuse large B-cell lymphoma have already demonstrated the superiority of novel immunotherapies over cytotoxic chemotherapy. Several single-arm pivotal studies of CAR T-cell therapies and BsAb therapies for relapsed/refractory FL have been conducted recently. Some of these agents have already been approved for the treatment of relapsed/refractory FL and are changing clinical practice dramatically. This manuscript summarizes available clinical data on CAR T-cell therapy and BsAb therapy for FL and briefly discusses future prospects.

CAR - t细胞疗法和双特异性抗体治疗复发/难治性滤泡性淋巴瘤。
滤泡性淋巴瘤(FL)是日本第二常见的淋巴瘤亚型。虽然FL是无法治愈的,但在没有组织学转化为侵袭性b细胞淋巴瘤的情况下,它通常有一个缓慢的临床过程。然而,一些患者,包括疾病进展在24个月内(POD24)和对利妥昔单抗和/或烷基化剂难治的患者,在接受常规细胞毒性化疗治疗时预后较差。目前,包括嵌合抗原受体(CAR) t细胞疗法和双特异性抗体(BsAb)疗法在内的几种新型免疫疗法正在开发中,用于治疗b细胞非霍奇金淋巴瘤。几项针对复发/难治性弥漫性大b细胞淋巴瘤的随机研究已经证明了新型免疫疗法优于细胞毒性化疗。最近,CAR - t细胞疗法和BsAb疗法治疗复发/难治性FL的单臂关键研究已经进行。其中一些药物已被批准用于治疗复发/难治性FL,并正在显著改变临床实践。本文总结了CAR - t细胞和BsAb治疗FL的现有临床资料,并简要讨论了未来的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信